Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05654051
Other study ID # ACTG A5371
Secondary ID UM1AI068636
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date October 1, 2021
Est. completion date August 30, 2023

Study information

Verified date December 2022
Source AIDS Clinical Trials Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of a drug called semaglutide and to see whether it can reduce IHTG. IHTG will be measured by magnetic resonance imaging (MRI; an MRI machine contains a powerful magnet that uses simple radio waves to take pictures of organs). Semaglutide (brand name Ozempic®) is a drug that is used to treat people who have diabetes; it also causes weight loss and may provide some protection against cardiovascular disease and diabetes. In PLWH, the use of semaglutide to reduce weight and the level of IHTG are experimental.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 51
Est. completion date August 30, 2023
Est. primary completion date August 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Two separate reports of HIV-1 RNA measurements <50 copies/mL, and no HIV-1 RNA measurement >500 copies/mL, during the 48 weeks prior to entry. - No change in ART in 24 weeks prior to entry or plans to change during study. - Not meeting criteria for diabetes but with central adiposity (i.e., minimum waist circumference of =95 cm for individuals assigned male sex at birth or =94 cm for individuals assigned female sex at birth), =5% IHTG content, plus at least one of the following indicators of insulin resistance or pre-diabetes: fasting plasma glucose 100-125 mg/dL, HbA1c between 5.7% and <6.5%, or HOMA-IR >3.0. - Documented evidence of immunity to hepatitis A virus (HAV) or documented history of HAV vaccination within 30 days prior to entry. - CD4+ T-cell count =200 cells/mm3 within 30 days prior to pre-entry. - The following laboratory values obtained within 30 days prior to pre-entry: 1. Absolute neutrophil count (ANC) >750 cells/mm3. 2. Hemoglobin >10 g/dL for individuals assigned male sex at birth and >9 g/dL for individuals assigned female sex at birth. 3. Creatinine clearance (CrCl) =50 mL/min, as calculated by the CKD-Epi equation. 4. Aspartate aminotransferase (AST) (SGOT) =3 x ULN on at least two measures. 5. Alanine aminotransferase (ALT) (SGPT) =3 x ULN on at least two measures. 6. Fasting triglyceride level =500 mg/dL. - For individuals prescribed daily medications with anti-inflammatory properties, the doses must be stable. - For individuals taking daily lipid-lowering medications, the doses must be stable. - Agree to use contraception if able to become pregnant. - For individuals taking vitamin E (any dose), the dose must be stable. Exclusion Criteria: - Pregnant, breastfeeding, or plans to become pregnant. - Known active hepatitis C virus (HCV) infection. - Active/chronic hepatitis B virus (HBV). - Known retinopathy (excluding remote history of cotton wool spots). - Known active severe delayed gastric emptying. - Gain or loss of >5% body weight within 12 weeks prior to study entry. - Any plans to change diet or exercise regimen significantly, except for the adoption of study-provided suggestions for diet and exercise, within the study period. - Known acute or chronic liver disease with cirrhosis or portal hypertension. - History of liver transplant. - Current diagnosis of diabetes mellitus or current use of diabetes medications, or a laboratory measurement of hemoglobin A1c =6.5% at screening. - Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). - History of unexplained hypercalcemia corrected for albumin that is >10.5 mg/dL. - Use of any immunomodulatory (including prednisone equivalent of =10 mg), HIV vaccine, investigational therapy, or TNF-a therapy within 3 months prior to study entry. - Use of human growth hormone, tesamorelin, supraphysiologic testosterone to achieve therapeutic blood levels, or any use of other anabolic steroids within 3 months prior to study entry or plans to start these while on study. - Use of estrogens or progesterones at supraphysiologic doses within 3 months prior to study entry. - Known allergy/sensitivity or any hypersensitivity to components of study drug or its formulation. - Current serious illness requiring systemic treatment and/or hospitalization. - Use of GLP-1 agonists within 24 weeks prior to study entry. - Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. - Excessive consumption of alcohol of =3 months within 90 days prior to screening. - Known chronic pancreatitis or more than one episode of pancreatitis ever in the past. - Intent to use any medication likely to cause significant changes in weight during the study period. - Use of stavudine within 12 months prior to study entry. - Prior bariatric surgery (e.g., lap band, gastric sleeve, or Roux-en-Y bypass surgery) or major gastric surgery or plans to undergo weight reduction surgery while on study. - Individuals with any metal, implantable devices (e.g., pacemakers, prosthetics), or shrapnel, per standard MRI exclusion criteria.

Study Design


Intervention

Drug:
Semaglutide
Semaglutide will be administered subcutaneously weekly into the abdomen, thigh or upper arm, and will be initiated at study entry at a dose of 0.25 mg once weekly, increased at week 2 to 0.5 mg once weekly, and finally increased to 1.0 mg once weekly at week 4 for continuation through week 24.

Locations

Country Name City State
Brazil 12101 Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS Rio de Janeiro
United States 6101 University of Colorado Hospital CRS Aurora Colorado
United States 201 Johns Hopkins University CRS Baltimore Maryland
United States 31788 Alabama CRS Birmingham Alabama
United States 101 Massachusetts General Hospital (MGH) CRS Boston Massachusetts
United States 2401 Cincinnati CRS Cincinnati Ohio
United States 31473 Houston AIDS Research Team (HART) CRS Houston Texas
United States 1401 University of Washington AIDS CRS Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
AIDS Clinical Trials Group National Institute of Allergy and Infectious Diseases (NIAID)

Countries where clinical trial is conducted

United States,  Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change (absolute) in intra-hepatic triglyceride (IHTG) (%) To evaluate whether 24 weeks of semaglutide will improve IHTG in ART-treated, adults with HIV, hepatic steatosis, central obesity, and insulin resistance or pre-diabetes. The primary comparison will examine the absolute change in IHTG from pre-entry to week 24. From pre-entry to week 24
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03383822 - Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT04203238 - Potato Research for Enhancing Metabolic Outcomes N/A
Recruiting NCT03658564 - Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance N/A
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03627104 - Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A
Active, not recruiting NCT03288025 - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) N/A
Completed NCT03809182 - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Phase 4
Completed NCT01809288 - Identifying Risk for Diabetes and Heart Disease in Women
Completed NCT04642482 - Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity Phase 4
Terminated NCT03278236 - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men? N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Withdrawn NCT04741204 - Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer Phase 4
Not yet recruiting NCT05540249 - Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG N/A